|Bid||165.22 x 900|
|Ask||165.76 x 800|
|Day's Range||161.86 - 173.50|
|52 Week Range||65.05 - 188.14|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||194.08|
NVRO earnings call for the period ending December 31, 2020.
Shares of Nevro (NYSE:NVRO) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 52.27% year over year to ($0.21), which beat the estimate of ($0.33). Revenue of $109,731,000 declined by 4.06% from the same period last year, which beat the estimate of $107,430,000. Guidance Nevro Sees Q1 Sales Of $84M-$86M Vs $94.23M Estimates Conference Call Details Date: Feb 24, 2021 Time: 04:30 PM View more earnings on NVRO ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwww.nevro.com%2F&eventid=2944669&sessionid=1&key=F528C36580B0D45AEC91FD0917977737®Tag=&V2=false&sourcepage=register Technicals Company's 52-week high was at $188.14 Company's 52-week low was at $65.05 Price action over last quarter: Up 6.73% Company Profile Nevro Corp is a medical device company. Its key product is the Senza spinal cord stimulation system, a neuromodulation platform for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. Nevro generates the majority of its revenue in the United States. It also receives nearly half of its revenue from Australia, the United Kingdom, and Germany. See more from BenzingaClick here for options trades from BenzingaNetApp: Q3 Earnings InsightsFidelity National Finl: Q4 Earnings Insights© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full year ended December 31, 2020 and provided 2021 guidance.